Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC

Francesco Di Costanzo, Silvia Gasperoni, Luigi Manzione, Giancarlo Bisagni, Roberto Labianca, Stefano Bravi, Enrico Cortesi, Paolo Carlini, Raffaella Bracci, Silverio Tomao, Luca Messerini, Annarosa Arcangeli, Valter Torri, Domenico Bilancia, Irene Floriani, Maurizio Tonato

Research output: Contribution to journalArticle

Abstract

Background: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m2, on days 1 and 5], epirubicin [30 mg/m2, days 1 and 5], L-leucovorin [100 mg/m2, days 1-4], and 5-fluorouracil [300 mg/m2, days 1-4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results: From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95% confidence interval [CI] = 0.66 to 1.27) or overall survival (HR of death = 0.90; 95% CI = 0.64 to 1.26). Conclusions: Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents.

Original languageEnglish
Pages (from-to)388-398
Number of pages11
JournalJournal of the National Cancer Institute
Volume100
Issue number6
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Disease-Free Survival
Survival
Recurrence
Drug Therapy
Confidence Intervals
Epirubicin
Mucositis
Leucovorin
Poisons
Leukopenia
Kaplan-Meier Estimate
Platinum
Proportional Hazards Models
Fluorouracil
Cisplatin
Vomiting
Meta-Analysis
Anemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant chemotherapy in completely resected gastric cancer : A randomized phase III trial conducted by GOIRC. / Di Costanzo, Francesco; Gasperoni, Silvia; Manzione, Luigi; Bisagni, Giancarlo; Labianca, Roberto; Bravi, Stefano; Cortesi, Enrico; Carlini, Paolo; Bracci, Raffaella; Tomao, Silverio; Messerini, Luca; Arcangeli, Annarosa; Torri, Valter; Bilancia, Domenico; Floriani, Irene; Tonato, Maurizio.

In: Journal of the National Cancer Institute, Vol. 100, No. 6, 03.2008, p. 388-398.

Research output: Contribution to journalArticle

Di Costanzo, F, Gasperoni, S, Manzione, L, Bisagni, G, Labianca, R, Bravi, S, Cortesi, E, Carlini, P, Bracci, R, Tomao, S, Messerini, L, Arcangeli, A, Torri, V, Bilancia, D, Floriani, I & Tonato, M 2008, 'Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC', Journal of the National Cancer Institute, vol. 100, no. 6, pp. 388-398. https://doi.org/10.1093/jnci/djn054
Di Costanzo, Francesco ; Gasperoni, Silvia ; Manzione, Luigi ; Bisagni, Giancarlo ; Labianca, Roberto ; Bravi, Stefano ; Cortesi, Enrico ; Carlini, Paolo ; Bracci, Raffaella ; Tomao, Silverio ; Messerini, Luca ; Arcangeli, Annarosa ; Torri, Valter ; Bilancia, Domenico ; Floriani, Irene ; Tonato, Maurizio. / Adjuvant chemotherapy in completely resected gastric cancer : A randomized phase III trial conducted by GOIRC. In: Journal of the National Cancer Institute. 2008 ; Vol. 100, No. 6. pp. 388-398.
@article{2ce86bd5b2cd4de69381c6c262f7c437,
title = "Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC",
abstract = "Background: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m2, on days 1 and 5], epirubicin [30 mg/m2, days 1 and 5], L-leucovorin [100 mg/m2, days 1-4], and 5-fluorouracil [300 mg/m2, days 1-4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results: From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1{\%}, 8.4{\%}, and 11.8{\%} of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3{\%}, 3.3{\%}, and 4.2{\%} of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6{\%}) experienced recurrence and 139 (53.9{\%}) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95{\%} confidence interval [CI] = 0.66 to 1.27) or overall survival (HR of death = 0.90; 95{\%} CI = 0.64 to 1.26). Conclusions: Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10{\%} reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents.",
author = "{Di Costanzo}, Francesco and Silvia Gasperoni and Luigi Manzione and Giancarlo Bisagni and Roberto Labianca and Stefano Bravi and Enrico Cortesi and Paolo Carlini and Raffaella Bracci and Silverio Tomao and Luca Messerini and Annarosa Arcangeli and Valter Torri and Domenico Bilancia and Irene Floriani and Maurizio Tonato",
year = "2008",
month = "3",
doi = "10.1093/jnci/djn054",
language = "English",
volume = "100",
pages = "388--398",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Adjuvant chemotherapy in completely resected gastric cancer

T2 - A randomized phase III trial conducted by GOIRC

AU - Di Costanzo, Francesco

AU - Gasperoni, Silvia

AU - Manzione, Luigi

AU - Bisagni, Giancarlo

AU - Labianca, Roberto

AU - Bravi, Stefano

AU - Cortesi, Enrico

AU - Carlini, Paolo

AU - Bracci, Raffaella

AU - Tomao, Silverio

AU - Messerini, Luca

AU - Arcangeli, Annarosa

AU - Torri, Valter

AU - Bilancia, Domenico

AU - Floriani, Irene

AU - Tonato, Maurizio

PY - 2008/3

Y1 - 2008/3

N2 - Background: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m2, on days 1 and 5], epirubicin [30 mg/m2, days 1 and 5], L-leucovorin [100 mg/m2, days 1-4], and 5-fluorouracil [300 mg/m2, days 1-4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results: From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95% confidence interval [CI] = 0.66 to 1.27) or overall survival (HR of death = 0.90; 95% CI = 0.64 to 1.26). Conclusions: Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents.

AB - Background: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m2, on days 1 and 5], epirubicin [30 mg/m2, days 1 and 5], L-leucovorin [100 mg/m2, days 1-4], and 5-fluorouracil [300 mg/m2, days 1-4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results: From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95% confidence interval [CI] = 0.66 to 1.27) or overall survival (HR of death = 0.90; 95% CI = 0.64 to 1.26). Conclusions: Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents.

UR - http://www.scopus.com/inward/record.url?scp=41449091327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41449091327&partnerID=8YFLogxK

U2 - 10.1093/jnci/djn054

DO - 10.1093/jnci/djn054

M3 - Article

C2 - 18334706

AN - SCOPUS:41449091327

VL - 100

SP - 388

EP - 398

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -